外排泵SmeDEF导致嗜麦芽窄食单胞菌对甲氧苄啶-磺胺甲恶唑耐药。
The efflux pump SmeDEF contributes to trimethoprim-sulfamethoxazole resistance in Stenotrophomonas maltophilia.
作者信息
Sánchez María Blanca, Martínez José Luis
机构信息
Departamento de Biotecnología Microbiana, Centro Nacional de Biotecnología, CSIC, Cantoblanco, Madrid, Spain.
Departamento de Biotecnología Microbiana, Centro Nacional de Biotecnología, CSIC, Cantoblanco, Madrid, Spain
出版信息
Antimicrob Agents Chemother. 2015 Jul;59(7):4347-8. doi: 10.1128/AAC.00714-15. Epub 2015 Apr 27.
Abstract
Trimethoprim-sulfamethoxazole (co-trimoxazole) is one of the antimicrobials of choice for the treatment of Stenotrophomonas maltophilia infections. The analysis of mutants either lacking or overexpressing the efflux pump SmeDEF shows that this efflux pump contributes to intrinsic and acquired co-trimoxazole resistance in S. maltophilia. Since SmeDEF can extrude a variety of antibiotics, selection with such antimicrobials, including quinolones, might also select for S. maltophilia co-trimoxazole resistance.
摘要
甲氧苄啶-磺胺甲恶唑（复方新诺明）是治疗嗜麦芽窄食单胞菌感染的首选抗菌药物之一。对缺失或过表达外排泵SmeDEF的突变体分析表明，该外排泵导致嗜麦芽窄食单胞菌对复方新诺明产生固有和获得性耐药。由于SmeDEF可以排出多种抗生素，使用包括喹诺酮类在内的此类抗菌药物进行选择，也可能导致嗜麦芽窄食单胞菌对复方新诺明产生耐药。
相似文献
1
The efflux pump SmeDEF contributes to trimethoprim-sulfamethoxazole resistance in Stenotrophomonas maltophilia.
Antimicrob Agents Chemother. 2015 Jul;59(7):4347-8. doi: 10.1128/AAC.00714-15. Epub 2015 Apr 27.
2
Overexpression of the Efflux Pumps SmeVWX and SmeDEF Is a Major Cause of Resistance to Co-trimoxazole in Stenotrophomonas maltophilia.
Antimicrob Agents Chemother. 2018 May 25;62(6). doi: 10.1128/AAC.00301-18. Print 2018 Jun.
3
Interplay between intrinsic and acquired resistance to quinolones in Stenotrophomonas maltophilia.
Environ Microbiol. 2014 May;16(5):1282-96. doi: 10.1111/1462-2920.12408. Epub 2014 Mar 4.
4
Levofloxacin Efflux and smeD in Clinical Isolates of Stenotrophomonas maltophilia.
Microb Drug Resist. 2017 Mar;23(2):163-168. doi: 10.1089/mdr.2015.0228. Epub 2016 Jun 13.
5
SmeDEF multidrug efflux pump contributes to intrinsic multidrug resistance in Stenotrophomonas maltophilia.
Antimicrob Agents Chemother. 2001 Dec;45(12):3497-503. doi: 10.1128/AAC.45.12.3497-3503.2001.
6
A function of SmeDEF, the major quinolone resistance determinant of Stenotrophomonas maltophilia, is the colonization of plant roots.
Appl Environ Microbiol. 2014 Aug;80(15):4559-65. doi: 10.1128/AEM.01058-14.
7
Role of Operon in Alleviation of Oxidative Stresses and Occurrence of Sulfamethoxazole-Trimethoprim-Resistant Mutants in Stenotrophomonas maltophilia.
Antimicrob Agents Chemother. 2018 Jan 25;62(2). doi: 10.1128/AAC.02114-17. Print 2018 Feb.
8
High-level quinolone resistance is associated with the overexpression of smeVWX in Stenotrophomonas maltophilia clinical isolates.
Clin Microbiol Infect. 2015 May;21(5):464-7. doi: 10.1016/j.cmi.2015.01.007. Epub 2015 Jan 23.
9
Risk factors and molecular mechanisms associated with trimethoprim-sulfamethoxazole resistance in Stenotrophomonas maltophilia in Mexico.
J Med Microbiol. 2017 Aug;66(8):1102-1109. doi: 10.1099/jmm.0.000550. Epub 2017 Aug 4.
10
The sul1 gene in Stenotrophomonas maltophilia with high-level resistance to trimethoprim/sulfamethoxazole.
Ann Lab Med. 2015 Mar;35(2):246-9. doi: 10.3343/alm.2015.35.2.246. Epub 2015 Feb 12.
引用本文的文献
1
of clinical origin display higher temperature tolerance comparing with environmental isolates.
Virulence. 2025 Dec;16(1):2498669. doi: 10.1080/21505594.2025.2498669. Epub 2025 May 8.
2
Cefiderocol for the Treatment of Nosocomial Bloodstream Infections Caused by Stenotrophomonas maltophilia: A Case Series and Literature Review.
Infect Dis Ther. 2025 Mar;14(3):657-669. doi: 10.1007/s40121-025-01117-2. Epub 2025 Mar 4.
3
Clinical presentation and outcomes of bloodstream infection with intrinsically carbapenem-resistant non-fermenting gram-negative organisms: Stenotrophomonas maltophilia, Elizabethkingia spp. and Chryseobacterium spp. in Singapore, from 2012 to 2024.
BMC Infect Dis. 2025 Feb 25;25(1):273. doi: 10.1186/s12879-025-10636-9.
4
: The Landscape in Critically Ill Patients and Optimising Management Approaches.
Antibiotics (Basel). 2024 Jun 22;13(7):577. doi: 10.3390/antibiotics13070577.
5
Antibiotic Susceptibility Profiling of Gram-Positive and Gram-Negative Bacterial Isolates in a Tertiary Care Hospital: Establishment of an Antibiogram.
Cureus. 2024 May 18;16(5):e60542. doi: 10.7759/cureus.60542. eCollection 2024 May.
6
complex: insights into evolutionary relationships, global distribution and pathogenicity.
Front Cell Infect Microbiol. 2024 Jan 10;13:1325379. doi: 10.3389/fcimb.2023.1325379. eCollection 2023.
7
Successful Treatment of Persistent Bacteremia With Cefiderocol in an Infant.
Open Forum Infect Dis. 2023 Mar 29;10(4):ofad174. doi: 10.1093/ofid/ofad174. eCollection 2023 Apr.
8
Versatility of : Ecological roles of RND efflux pumps.
Heliyon. 2023 Mar 28;9(4):e14639. doi: 10.1016/j.heliyon.2023.e14639. eCollection 2023 Apr.
9
Evolution and Emergence of Antibiotic Resistance in Given Ecosystems: Possible Strategies for Addressing the Challenge of Antibiotic Resistance.
Antibiotics (Basel). 2022 Dec 24;12(1):28. doi: 10.3390/antibiotics12010028.
10
MDR Pumps as Crossroads of Resistance: Antibiotics and Bacteriophages.
Antibiotics (Basel). 2022 May 30;11(6):734. doi: 10.3390/antibiotics11060734.
本文引用的文献
1
Contribution of resistance-nodulation-cell division efflux systems to antibiotic resistance and biofilm formation in Acinetobacter baumannii.
mBio. 2015 Mar 24;6(2):e00309-15. doi: 10.1128/mBio.00309-15.
2
Comparisons between patients with trimethoprim-sulfamethoxazole-susceptible and trimethoprim-sulfamethoxazole-resistant Stenotrophomonas maltophilia monomicrobial bacteremia: A 10-year retrospective study.
J Microbiol Immunol Infect. 2016 Jun;49(3):378-86. doi: 10.1016/j.jmii.2014.06.005. Epub 2014 Jul 28.
3
A function of SmeDEF, the major quinolone resistance determinant of Stenotrophomonas maltophilia, is the colonization of plant roots.
Appl Environ Microbiol. 2014 Aug;80(15):4559-65. doi: 10.1128/AEM.01058-14.
4
Interplay between intrinsic and acquired resistance to quinolones in Stenotrophomonas maltophilia.
Environ Microbiol. 2014 May;16(5):1282-96. doi: 10.1111/1462-2920.12408. Epub 2014 Mar 4.
5
Multidrug resistance in clinical isolates of Stenotrophomonas maltophilia: roles of integrons, efflux pumps, phosphoglucomutase (SpgM), and melanin and biofilm formation.
Int J Antimicrob Agents. 2010 Feb;35(2):126-30. doi: 10.1016/j.ijantimicag.2009.09.015. Epub 2009 Nov 18.
6
Stenotrophomonas maltophilia drug resistance.
Future Microbiol. 2009 Aug;4(6):655-60. doi: 10.2217/fmb.09.45.
7
The complete genome, comparative and functional analysis of Stenotrophomonas maltophilia reveals an organism heavily shielded by drug resistance determinants.
Genome Biol. 2008 Apr 17;9(4):R74. doi: 10.1186/gb-2008-9-4-r74.
8
A molecular biological protocol to distinguish potentially human pathogenic Stenotrophomonas maltophilia from plant-associated Stenotrophomonas rhizophila.
Environ Microbiol. 2005 Nov;7(11):1853-8. doi: 10.1111/j.1462-2920.2005.00928.x.
9
Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit.
Diagn Microbiol Infect Dis. 2005 Jul;52(3):203-8. doi: 10.1016/j.diagmicrobio.2005.05.002.
10
Analysis of sequence variation among smeDEF multi drug efflux pump genes and flanking DNA from defined 16S rRNA subgroups of clinical Stenotrophomonas maltophilia isolates.
J Antimicrob Chemother. 2004 Aug;54(2):348-53. doi: 10.1093/jac/dkh367. Epub 2004 Jul 14.
Zotero 插件